Testing safety of PYC-003 for ADPKD
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ADPKD (a type of inherited kidney disease).
- You are between 18 and 65 years old.
- Your kidney function (eGFR) is at least 30 mL/min (moderate or better kidney function).
- You are not currently taking tolvaptan or metformin for your kidney disease.
- You have not had gene therapy, cell therapy, or RNA therapy for any kidney condition.
- You are willing to avoid alcohol and tobacco products during the study and to follow contraception rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests whether a short-term diet can help people with autosomal dominant polycystic kidney disease (ADPKD). You would follow a special diet for one week to see how it affects your health.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study enrolls adults with autosomal dominant polycystic kidney disease (ADPKD) to better understand the disease and its related changes in the body. It may help researchers find improved ways to track the condition and support future treatments.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This study looks at how the body’s “Nrf2 response” works in people with autosomal dominant polycystic kidney disease (ADPKD). It may help researchers better understand disease biology and future treatments by comparing kidney-related signals in ADPKD patients and healthy volunteers.
This study looks at people with autosomal dominant polycystic kidney disease to learn more about the condition. It is an observational study, meaning no new treatments are tested—just gathering information from your medical history and tests.
Hear when a new Autosomal Dominant Polycystic Kidney Disease (ADPKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.